https://www.selleckchem.com/pr....oducts/ag-120-Ivosid
9% vs. 4.6%), and dysgeusia (24.3% vs. 11.9%). Discontinuation rates due to adverse events (AE) (7.0% vs. 0.9%) yielded NNH=17. LHH comparing MADRS remission vs. discontinuation due to AE was 17 vs. 6. Maintenance use of esketamine+AD demonstrated NNT values less then 10 for relapse and/or maintenance of remission. In maintenance study, discontinuation due to AE (2.6% vs. 2.1%) yielded NNH=178 (non-significant). Limitations Only dichotomous outcomes were included. Conclusion NNT less then 10 for efficacy outcomes suggests pote
Like
Comment
Share
